If a company files for Chapter 7 bankruptcy, that means it's heading for liquidation, in which assets are sold off to pay creditors.

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of 22.1%, reaching US$8.85 billion in 2025 and an impressive US$24.00 billion by ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Migraine is the third most common illness in the world, with about 14 percent of the global population experiencing migraine ...

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ...

We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Qulipta currently has no reports of interacting with Nurtec, better known as Nurtec ODT (rimegepant). Both Qulipta and Nurtec ODT belong to a group of drugs called CGRP antagonists. Both drugs ...

Currently, AbbVie’s Ubrelvy (ubrogepant) and Pfizer’s Zavzpret (zavegepant) and Nurtec (rimegepant) are available for acute treatment in the US. To intensify the competition, novel drug combinations ...

Additional competition also comes from two orally administered gepants: Pfizer’s Nurtec (rimegepant) and AbbVie’s Qulipta (atogepant). KOLs agreed that the CGRP mAbs had similar efficacy profiles, ...